



2017/10/10

Company:	CYBERDYNE, INC.
Name of Representative:	Yoshiyuki Sankai, President and CEO
Code:	7779 (Mothers Section of the Tokyo Stock Exchange)
Contact:	Shinji Uga, Director and CFO (Tel. +81-29-869-9981)

### **AMED adopts CYBERDYNE's research proposal on HAL Single Joint Type for "Project to Accelerate Medical Device Development"**

A joint proposal of CYBERDYNE, INC. (the "Company") with Kyoto University (Representative Institution of Research and Development" and Fukuoka University on "investigator initiated clinical trial of HAL Single Joint Type on upper limb" was adopted by Japan Agency for Medical Research and Development ("AMED") for its solicited project on "clinical research and investigator initiated clinical trial of venture company originated innovative medical devices" as part of "Project to Accelerate Medical Device Development".

It must be noted that this research project is aimed at delivering safe medical technology to the Japanese people at the earliest opportunity. In order to convert the result of basic researches to acquirement of medical device approval, the clinical research of this project is designed to provide quality outcome from both scientific and ethical perspective.

1. Name of the research project: Investigator initiated clinical trial of HAL Single Joint Type on upper limb
2. Representative Institution of Research and Development: Kyoto University Department of Neurosurgery
3. Assigned research task of the Company: Supply of devices, information management and device management support
4. Schedule: The Company plans to post the research grant as non-operative income for the Fiscal Year ending March 31, 2018. The amount has not yet been determined.